[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628251":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":18,"responsibleParty":35,"collaborators":10,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":10,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":10,"enrollmentInfo":47,"targetDuration":10,"studyType":50,"phases":10,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"68Ga-1A12 PET",null,"Evaluation of 68Ga-1A12 imaging in assessing the diagnostic validity of various types of fibrosis-related diseases, including calculation of its sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Xiao Chen, PH .D","CONTACT","15922970174","xiaochen229@tmmu.edu.cn",[19],{"facility":20,"status":10,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"Daping Hospital","Chongqing","Chongqing Municipality","400010","China","CN",{"type":27,"coordinates":28},"Point",[29,30],106.55771,29.56026,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":16,"phoneExt":10,"email":17},"Daping Hospital xiao chen, PH.D",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Xiao Chen","Director of Nuclear Medicine Department","100628251","clinical-application-of-68ga-1a12-pet-in-fibrosis-related-diseases-100628251",false,"NCT07459205","Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases","Inclusion Criteria:\n\n* No gender restriction, age ≥18 years (inclusive);\n* patients suspected or confirmed to have fibrosis-related disease;\n* patients eligible for 68Ga-1A12 PET scan\n* Patients who can provide informed consent (signed by the participant, parent or legal representative) and consent forms in accordance with the guidelines of the clinical research ethics committee.\n\nExclusion Criteria:\n\n* patients in critical condition requiring emergency care;\n* Individuals with druand\u002For alcohol abuse, or those with allergic predisposition;\n* women of childbearing potential, pregnant and lactating women;\n* bacterial, viral or fungal infections that require systemic treatment;\n* The study excluded participants deemed unsuitable by the investigators.","ALL","18 Years",{"count":48,"type":49},50,"ESTIMATED","OBSERVATIONAL","Organ fibrosis is a common end-stage pathological change in various chronic diseases, characterized by excessive deposition of extracellular matrix (ECM) and disruption of tissue architecture, which can involve multiple organs such as the heart, liver, lungs, kidneys, and intestines. Although the pathogenic triggers vary, the core molecular mechanisms are highly conserved, involving sustained activation of signaling pathways such as transforming growth factor-β (TGF-β), transdifferentiation of fibroblasts into myofibroblasts, and processes like epithelial-mesenchymal transition (EMT) . Currently, histopathological biopsy remains the gold standard for the diagnosis and staging of fibrosis, but its inherent invasiveness, sampling errors, and procedural risks limit its repeated application and dynamic monitoring .\n\nIn clinical practice, functional imaging modalities such as high-resolution computed tomography (CT) and ultrasonic elastography have been employed to assess fibrosis in specific organs (e.g., lungs, liver). However, these methods predominantly rely on secondary morphological or physical property alterations, exhibiting limited capacity for identifying early-stage, active molecular-level pathological processes. Additionally, they are challenging to perform for systemic, multi-target quantitative evaluation.",[53],"Pulmonary Fibrosis",[55,56,53],"PET","68Ga-1A12","NOT_YET_RECRUITING","2026-03-08",{"date":60,"type":61},"2026-03-11","ACTUAL",{"date":63,"type":49},"2026-03-01",{"date":65,"type":49},"2027-12-31",{"name":5,"class":6},1]